Recent policy changes help increase access to recommended non-invasive colorectal cancer screening tests. These policy changes require Medicare and most commercial insurers to pay for colonoscopy after a positive Cologuard test without cost to the patient. For most patients, these financial protections take effect starting Jan. 1.
At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).
